DeFronzo, R. A. Pathogenesis of type 2 diabetes mellitus. Med. Clin. N. Am. 88, 787–835 (2004).
Tripathi, B. K. & Srivastava, A. K. Diabetes mellitus: Complications and therapeutics. Med Sci Monit. 12, RA130–RA147 (2006).
Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053 (2004).
Saeedi, P. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 157, 107843 (2019).
Cefalu, W. T., Rubino, F. & Cummings, D. E. Metabolic surgery for type 2 diabetes: Changing the landscape of diabetes Care. Diabetes Care 39, 857–860 (2016).
Rubino, F. & Cummings, D. E. Surgery: The coming of age of metabolic surgery. Nat. Rev. Endocrinol. 8, 702–704 (2012).
Rubino, F. & Marescaux, J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: A new perspective for an old disease. Ann. Surg. 239, 1–11 (2004).
Guan, W. et al. Duodenal-jejunal exclusion surgery improves type 2 diabetes in a rat model through regulation of early glucose metabolism. Can. J. Diabetes. 44, 401-406.e1 (2020).
Dolo, P. R. et al. Preserving duodenal-jejunal (foregut) transit does not impair glucose tolerance and diabetes remission following gastric bypass in type 2 diabetes Sprague Dawley rat model. Obes. Surg. 28, 1313–1320 (2018).
Kashihara, H. et al. Duodenal-jejunal bypass improves insulin resistance by enhanced glucagon-like peptide-1 secretion through increase of bile acids. Hepatogastroenterology. 61, 1049–1054 (2014).
Seki, Y., Kasama, K., Umezawa, A. & Kurokawa, Y. Laparoscopic sleeve gastrectomy with duodenojejunal bypass for type 2 diabetes mellitus. Obes. Surg. 26, 2035–2044 (2016).
Cavin, J.-B. et al. Differences in alimentary glucose absorption and intestinal disposal of blood glucose following Roux-en-Y gastric bypass vs sleeve gastrectomy. Gastroenterology 150, 454-464.e9 (2016).
Saeidi, N. et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science 341, 406–410 (2013).
Mumphrey, M. B., Hao, Z., Townsend, R. L., Patterson, L. M. & Berthoud, H.-R. Sleeve gastrectomy does not cause hypertrophy and reprogramming of intestinal glucose metabolism in rats. Obes. Surg. 25, 1468–1473 (2015).
Hansen, C. F. et al. Hypertrophy dependent doubling of L-cells in Roux-en-Y gastric bypass operated rats. PLoS ONE 8, e65696 (2013).
Kellett, G. L. The facilitated component of intestinal glucose absorption. J. Physiol. 531, 585–595 (2001).
Kellett, G. L. & Brot-Laroche, E. Apical GLUT2: A major pathway of intestinal sugar absorption. Diabetes 54, 3056–3062 (2005).
Koepsell, H. Glucose transporters in the small intestine in health and disease. Pflugers Arch. 472, 1207–1248 (2020).
Wright, E. M., Loo, D. D. F. & Hirayama, B. A. Biology of human sodium glucose transporters. Physiol. Rev. 91, 733–794 (2011).
Thorens, B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am. J. Physiol. 270, G541–G553 (1996).
Courcoulas, A. P. et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: A randomized clinical trial. JAMA Surg. 150, 931–940 (2015).
Cummings, D. E. et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia 59, 945–953 (2016).
Fruhbeck, G. Bariatric and metabolic surgery: A shift in eligibility and success criteria. Nat. Rev. Endocrinol. 11, 465–477 (2015).
Mingrone, G. et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386, 964–973 (2015).
Schauer, P. R. et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N. Engl. J. Med. 376, 641–651 (2017).
Schauer, P. R. et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann. Surg. 238, 467–484 (2003).
Fried, M. et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI < 35 kg/m2: An integrative review of early studies. Obes. Surg. 20, 776–790 (2010).
Laferrère, B. Do we really know why diabetes remits after gastric bypass surgery?. Endocrine 40, 162–167 (2011).
Cummings, D. E. Metabolic surgery for type 2 diabetes. Nat. Med. 18, 656–658 (2012).
Bradley, D. et al. Gastric bypass and banding equally improve insulin sensitivity and β cell function. J. Clin. Investig. 122, 4667–4674 (2012).
Han, H. et al. Expedited biliopancreatic juice flow to the distal gut benefits the diabetes control after duodenal-jejunal bypass. Obes. Surg. 25, 1802–1809 (2015).
Breen, D. M. et al. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat. Med. 18, 950–955 (2012).
Taqi, E. et al. The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. J. Pediatr. Surg. 45, 987–995 (2010).
Bueter, M. et al. Gastric bypass increases energy expenditure in rats. Gastroenterology 138, 1845–1853 (2010).
Kwon, I. G. et al. Serum glucose excretion after Roux-en-Y gastric bypass: A potential target for diabetes treatment. Gut 70, 1847–1856 (2021).
Sanaksenaho, G. et al. Parenteral nutrition-dependent children with short-bowel syndrome lack duodenal-adaptive hyperplasia but show molecular signs of altered mucosal function. JPEN J. Parenter. Enteral. Nutr. 44, 1291–1300 (2020).
Jiang, B. et al. Role of proximal intestinal glucose sensing and metabolism in the blood glucose control in type 2 diabetic rats after duodenal jejunal bypass surgery. Obes. Surg. 32(4), 1119–1129 (2022).
Tack, J., Arts, J., Caenepeel, P., Wulf, D. D. & Bisschops, R. Pathophysiology, diagnosis and management of postoperative dumping syndrome. Nat. Rev. Gastroenterol. Hepatol. 6, 583–590 (2009).
Tack, J. & Deloose, E. Complications of bariatric surgery: Dumping syndrome, reflux and vitamin deficiencies. Best Pract. Res. Clin. Gastroenterol. 28, 741–749 (2014).
Borgmann, D. et al. Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism. Cell Metab. 33, 1466–1482 (2021).
Wang, P. Y. et al. Upper intestinal lipids trigger a gut–brain–liver axis to regulate glucose production. Nature 452, 1012–1016 (2008).
Soty, M., Gautier-Stein, A., Rajas, F. & Mithieux, G. Gut–brain glucose signaling in energy homeostasis. Cell Metab. 25, 1231–1242 (2017).
Stearns, A. T. et al. Rapid upregulation of sodium-glucose transporter SGLT1 in response to intestinal sweet taste stimulation. Ann. Surg. 251, 865–871 (2010).
Stearns, A. T., Balakrishnan, A., Rhoads, D. B. & Tavakkolizadeh, A. Rapid upregulation of sodium-glucose transporter SGLT1 in response to intestinal sweet taste stimulation. Ann. Surg. 251, 865–871 (2010).
Stearns, A. T. et al. Capsaicin-sensitive vagal afferents modulate posttranscriptional regulation of the rat Na+/glucose cotransporter SGLT1. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G1078–G1083 (2008).
Yang, Y. et al. Pyridostigmine regulates glucose metabolism and mitochondrial homeostasis to reduce myocardial vulnerability to injury in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 317, E312–E326 (2019).
Simonen, M. et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes. Surg. 22(9), 1473–1480 (2012).
Chai, J. et al. Mechanism of bile acid-regulated glucose and lipid metabolism in duodenal-jejunal bypass. Int. J. Clin. Exp. Pathol. 8(12), 15778–15785 (2015).
Chadt, A. & Al-Hasani, H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pflugers Arch. 472(9), 1273–1298 (2020).
Ding, L., Yang, L., Wang, Z. & Huang, W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm. Sin. B. 5(2), 135–144 (2015).
Rubino, F. et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann. Surg. 244, 741–749 (2006).
Okikawa, S. et al. Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer. Oncol. Rep. 47, 71 (2022).
Otani, T. et al. Non-invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG-PET/CT and CT. Oncol. Rep. 41, 447–454 (2019).